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Abstract
Introduction—Fibrinogen is a key component of the blood coagulation system and plays
important, diverse roles in several relevant pathologies such as thrombosis, hemorrhage, and
cancer. It is a large glycoprotein whose three-dimensional molecular structure is not fully known.
Furthermore, circulating fibrinogen is highly heterogeneous, mainly due to proteolytic degradation
and alternative mRNA processing. Recombinant production of human fibrinogen allows
investigating the impact on the three-dimensional structure of specific changes in the primary
structure.
Methods—We performed analytical ultracentrifugation analyses of a full-length recombinant
human fibrinogen, its counterpart purified from human plasma, and a recombinant human
fibrinogen with both Aα chains truncated at amino acid 251, thus missing their last 359 amino
acid residues.
Results—We have accurately determined the translational diffusion and sedimentation
coefficients ( , ) of all three species. This was confirmed by derived molecular weights
within 1% for the full length species, and 5% for the truncated species, as assessed by comparison
with SDS-PAGE/Western blot analyses and primary structure data. No significant differences in
the values of  and  were found between the recombinant and purified full length
human fibrinogens, while slightly lower and higher values, respectively, resulted for the
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recombinant truncated human fibrinogen compared to a previously characterized purified human
fibrinogen fragment X obtained by plasmin digestion.
Conclusions—Full-length recombinant fibrinogen is less polydisperse but hydrodynamically
indistinguishable from its counterpart purified from human plasma. Recombinant Aα251-
truncated human fibrinogen instead behaves differently from fragment X, suggesting a role for the
Bβ residues 1–52 in inter-molecular interactions. Overall, these new hydrodynamic data will
constitute a reliable benchmark against which models of fibrinogen species could be compared.
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INTRODUCTION
Fibrinogen (FG) is a high molecular weight (~340,000), very elongated (length ~45 nm)
plasma glycoprotein playing a central role in the blood coagulation system of vertebrates.
FG is also implicated in various pathologies like thrombosis, hemorrhage, and cancer [1–3].
In plasma, FG is a heterogeneous mixture of several variants that differ mainly in primary
amino acid structure. At the basic level, all variants are composed of two pairs each of three
different chains (Aα, Bβ and γ) whose N-termini reside in a central globular domain (“E”
region), from which they symmetrically depart forming two triple coiled-coil connectors
held in register by two “disulfide rings” [4–7]. At the end of each connector, after the second
disulfide ring, the Bβ and γ chains C-terminals fold separately forming two outer globular
domains (“D” regions), while the Aα chains revert their direction forming a fourth coiled
helix at least up to residue Aα200 and Aα219 in the human and chicken species,
respectively, as determined by X-ray crystallography [7–9]. The structure and location of the
remaining 411 C-terminal residues (human numbering) of the Aα chains (AαC regions) is
still undetermined, and has been alternatively proposed to behave as a free-swimming
appendage [4, 8–9], or to form a fourth globular domain on top of the E region [10–14].
Only a small portion of the bovine species C-terminus (corresponding to residues Aα425–
502 in the human species) has been proved to be at least partially structured by NMR and
other biophysical methods [15–18]. An additional unique feature of the AαC regions is the
presence among species of a variable number (e.g., eleven in the human, none in the
chicken) of 13-amino acids repeats [19–21], located between the end of the fourth coiled
helix and the partially structured region. Furthermore, the AαC region is also highly
susceptible to proteolytic degradation (in 25 % of the plasma FG the C-terminus of the Aα
chain is degraded on one side of the molecule, and in 5% both Aα chains are degraded),
which, coupled with other post-transcriptional and post-translational modifications like
partial AαSer3 and other Ser/Thr residues phosphorylation [22], renders circulating FG
highly polydisperse [23]. The N-terminal 16 and 14 amino acid residues of the Aα and Bβ
chains, respectively, are cleaved off by thrombin during FG enzymatic activation yielding
fibrin monomer (α2β2γ2) [1,2]. The released peptides are known as fibrinopeptides A and
B, respectively (FpA and FpB).
Hydrodynamic parameters, such as the infinite-dilution translational diffusion and
sedimentation coefficients (  and ), can be effectively used in multi-resolution
modeling of biomacromolecules, helping to discriminate between alternative conformations
(e.g., [24]; see also [25]). In a previous publication, we have reported the hydrodynamic and
mass spectrometric characterization of a highly purified, nearly intact human plasma FG
fraction (hpHMW-FG), of a controlled plasmin proteolysis human FG product lacking the
AαC regions, termed fragment X (hpFrX-FG), and of chicken plasma FG (cpFG) [26]. We
present here the results of new analytical ultracentrifugation sedimentation velocity (AUC-
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SV) experiments on a similar hpHMW-FG preparation, and on two human FG recombinant
species, full-length (hrHMW-FG, from the commercial source ProFibrix), and with the Aα
chain truncated after residue 251 (hrα251-FG, prepared in our laboratories). We were able
to determine  and  accurately, and complemented them with Aα chain
polydispersity and Fp content analyses. Together these results establish benchmark data that




All chemicals were reagent grade from Merck (VWR International, Milano, Italy; http://
www.merck-chemicals.com/) or from Sigma-Aldrich (St. Louis, MO; http://
www.sigmaaldrich.com/united-states.html), unless otherwise stated, and double-distilled
water was used in the preparation of all the solutions. DU640 and DU800
spectrophotometers (Beckman Coulter, Fullerton, CA; http://www.beckmancoulter.com)
were used for all spectrophotometric operations. Quality control and characterization of the
samples by polyacrylamide (PAA) gel electrophoresis in the presence of sodium dodecyl
sulphate (SDS–PAGE) and Western blotting, followed by densitometric analyses, was done
as previously extensively reported [26].
Human plasma high molecular weight fibrinogen purification
hpHMW-FG was purified by (NH4)2SO4 fractional precipitation from lyophilized human
fibrinogen (hFG; plasminogen depleted, type FIB1 from Enzyme Research Laboratories,
South Bend, IN; http://www.enzymeresearch.com/), after reconstitution and dialysis into an
appropriate buffer, as previously described in detail [26].
Human recombinant high molecular weight fibrinogen preparation and purification
hrHMW-PG was obtained from ProFibrix, Leiden, The Netherlands (http://
www.profibrix.com/), and was prepared and purified as previously described [27].
Human recombinant Aα251 truncated fibrinogen preparation and purification
Media with recombinant hrα251-FG, having intact Bβ and γ chains and the Aα chain
truncated after residue 251 [28], were purchased from the National Cell Culture Center
(Biovest International, Minneapolis, MN, USA; http://www.biovest.com/) and purified by
salt precipitation and immunoaffinity chromatography using the calcium-dependent FG-
specific monoclonal antibody IF-1 (Kamiya Biomedical, Seattle, WA, USA; http://
www.kamiyabiomedical.com/) as described [29,30].
Briefly, hrα251-FG was precipitated from the medium overnight at 4 °C with 33% saturated
(NH4)2SO4. After centrifugation, the pellet was dissolved in loading buffer (Tris
(tris(hydroxymethyl)aminomethane) 20 mM, NaCl 0.3 M, pH 7.4) with 10 mM CaCl2 and
loaded onto the pre-equilibrated IF-1 column. After washing steps with Tris 20 mM, NaCl 1
M, CaCl2 10 mM, pH 7.4, and CH3COONa 50 mM, NaCl 0.3 M, CaCl2 10 mM, pH 6.0,
hrα251-FG was eluted with Tris 20 mM, NaCl 0.3 M, EDTA-Na2 5 mM, pH 7.4, dialyzed
once against loading buffer with 1 mM CaCl2 and then twice against Tris Buffered Saline
(TBS; Tris 50 mM, NaCl 104 mM, aprotinin 10 KIU/ml, pH 7.4). Several batches were
purified. Each was tested by SDS-PAGE under reducing and non reducing conditions.
Subsequently, Western blotting was performed using rabbit polyclonal antibodies to human
FG (Dako Corp, code N A0080, Carpinteria, CA; http://www.dako.com/) and the
monoclonal antibody Y18 (a gift from Dr. Nieuwenhuizen, Leiden, The Netherlands)
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specific for the N-terminus of the Aα-chain [31]. All batches were found to be > 97%
clottable.
Different hrα251-FG batches were pooled together, concentrated by ultrafiltration (Amicon
Ultra-15, MWCO 100, Millipore, Billerica, MA; http://www.millipore.com) to 10 mg/ml
(concentration above which hrα251-FG tends to precipitate), added with 1 mM AESBF (4-
(2-aminoethyl) benzenesulfonyl fluoride hydrochloride, Sigma–Aldrich) and stored at −80
°C until use.
Fibrinopeptides analysis
Fibrinopeptides release and analysis by RP-HPLC was done essentially as previously
reported [32], with some modifications. In short, 140 μL of reaction mixture contained FG
species at 0.5 mg/ml and thrombin (Sigma-Aldrich) at 0.25 nominal NIH units/ml in TBS.
After 2 h of incubation at 25 °C, the reaction was stopped by immersion in boiling water for
1 min, followed by centrifugation at 16,000g for 15 min. The supernatant was filtered on
polyethylene sulfone 0.45 μm pore-size filters (Millipore) and 40 μL were injected on a 1.0
× 150 mm, 300 Å pore size, 3.5 μm particle size Symmetry 300 C18 column, protected by a
Symmetry 300 C18 2.1 × 10 mm pre-column (Waters Corp., Milford, MA, USA; http://
www.waters.com). The HPLC set-up consisted of an Agilent 1200 series system, equipped
with G1379B degasser, G1376A capillary pump, G1377A micro autosampler, G1316A
thermostatted column holder, and G1315B diode array detector. It was equilibrated in 97%
25 mM CH3COONH4, brought to pH 6 with diluted H3PO4 (buffer A), and 3% 50 mM
CH3COONH4, brought to pH 6 with diluted H3PO4 and then diluted 1:1 with CH3CN
(buffer B). CH3COONH4 was from Fluka (Sigma-Aldrich) and CH3CN was LiChroSolv
from Merck. The flow rate was 50 μl/min, and the elution was performed in this sequence:
isocratic 97% A - 3% B for 8 min, then three linear gradients, the first in 5 min to 12% B,
the second in 45 min to 27% B, and the third in 6 min to 100% B, and finally maintained at
100% B for 5 min. The elution was monitored at 211 nm, and the columns were
thermostatted at 30 °C.
Analytical Ultracentrifugation
AUC-SV experiments were performed using a Beckman Coulter (Palo Alto, CA, USA)
Optima XLI Analytical Ultracentrifuge. In each experiment, sample solutions (400 μl) of
various concentrations (~0.1–1.6 mg/ml) and TBS buffer (410 μl) were loaded into the
sample and reference channels, respectively, of seven double sector, 12 mm optical
pathlength Epon centerpiece cells. After loading, the samples were spun for a few minutes at
3000 rpm to check for leaks and to record an absorbance scan (200–340 nm) used to
calculate the actual sample concentration in each cell. Samples were then centrifuged at
40,000 rpm at a constant temperature of 20.0 °C. Concentration profiles and the movement
of the sedimenting boundary in the AUC cell were recorded using the Rayleigh interference
optical system. AUC-SV data were analyzed by continuous size distribution analysis c(s)
using Sedfit 12.0 [33] (available at http://www.analyticalultracentrifugation.com). All the
c(s) distributions were calculated with a fitted frictional ratio f/f0 and a maximum entropy
regularization procedure with a confidence level of 0.68. All the diffusion values were
calculated from the fitted sedimentation coefficient and frictional ratio, as well as the
deduced molecular mass from these parameters. Standard deviation on fitted f/f0
measurement was calculated using confidence interval search in Sedphat 10.40 [33]. Theory
is described in previously published work [26].
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The molecular characterization and quality control of the samples are illustrated in Figs. 1–
3. In Fig. 1, panels A and B, SDS-PAGE analyses of non reduced and reduced samples,
respectively, of hpHMW-FG, hrHMW-FG, and hrα251-FG are shown. As can be seen,
mainly single bands are visible in the non reduced samples, with a slight trace of higher
molecular weight species only in hpHMW-FG. As for the reduced samples, hrHMW-FG has
a single top band, corresponding to the Aα chain, while hpHMW-FG shows the
characteristic doublet indicating a certain degree of size polydispersity. In the hrα251-FG
samples, the Aα chain is the last visible band migrating just above the 31 kD marker. The
Bβ and γ chains appear to be indistinguishable in all samples. Since the major source of
polydispersity resides in the Aα chain, with C-terminal degradation products that can
migrate together with the Bβ and γ chains, Western blot analyses using the Y-18 mAb
specific for the N-terminal end of the Aα chain [31] was done. The results are shown in Fig.
1, panel C, where the lesser amount of C-terminally degraded Aα chains in the hrHMW-FG
sample compared to hpHMW-FG samples is already evident in the two leftmost lanes (both
were loaded with roughly the same total amount of protein). This is confirmed by the
densitometric analyses shown in Fig. 2, where the better homogeneity of the hrHMW-FG
sample (panel A) in respect to the hpHMW-FG sample (panel B) can be fully appreciated.
Note that, due to the absence of the doublet in the hrHMW-FG sample, the densitometry was
performed on a lane loaded with half the total amount of the other lanes (rightmost lane in
Fig. 1, panel C), to avoid saturation of the main band.
The densitometry traces were then deconvolved using the EMG-GMG (exponentially
modified Gaussian plus half-Gaussian modified Gaussian) chromatography function
available in PeakFit v.4 (Jandel Scientific, now distributed by Systat Software Inc.,
Richmond, CA; http://www.sigmaplot.com/) [26], with a quadratic or a non-parametric
baseline to account for the non-uniform background and avoid overestimation of the smaller
peaks areas (tolerance ~1%). Typical results are shown in Fig. 2, panels C and D, but given
the relatively minor effect of the smaller peaks on global computer parameters (see below), a
rigorous quantization using multiple gels at different loading ratios was not attempted. For
the traces examined, although many solutions could fit them almost equally well, a
consensus emerged in which the main peak in hrHMW-FG (Fig. 2, panel C) derives from
the contribution of a relatively small front component (blue), two main components (green
and magenta, with a predominance of the slower migrating one), plus a very small trailing
component (gray). The corresponding analysis for hpHMW-FG showed that the main twin
peaks have a reduced amount or even lacked the front component (a small bump is observed
in a compatible position), while the main components included also the small trailing
component seen in hrHMW-FG, all three now in similar proportions (Fig. 2, panel D; see
also Table 1). By comparison with the results of mass-spectrometry and SDS-PAGE/
Western blot analyses on similar FG samples previously carried out in our labs [26,34], we
could assign the two main peaks in hrHMW-FG and hpHMW-FG to Aα1-610 and
Aα1-601, while the very small trailing peak in hrHMW-FG, becoming the third main peak
in hpHMW-FG, is likely Aα1-583. As for the front component in hrHMW-FG, it could
correspond to the 66,942 mass that we previously found in small amounts when analyzing
hpHMW-FG [26], and in both cases it might represent a mixture of the Aα1-610 O-
glycosylated forms (plus phosphorylated serines in hpHMW-FG, see below) recently shown
to represent 1–13% of human plasma FG [35]. Its near absence in the current hpHMW-FG
preparation likely results from purification variability. The other peaks corresponding to C-
terminally degraded forms of Aα chains where found to be positioned at the same locations
in both samples, and were assigned, again by comparison with our previous results and for
hrHMW-FG with densitometry of lanes loaded with more material (data not shown), to Aα
chains species down to Aα1-424. The final results of these analyses are reported in Table 1,
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together with the molecular masses, extinction coefficients (E280) and partial specific
volumes (v̄) calculated from the composition of the polypeptides using PROMOLP [36]. No
densitometric analyses were conducted on the hrα251-FG sample, as a single Aα chain
band was evident. Note that the computed values for the hrHMW-FG and hpHMW-FG Aα
chain species differ slightly because, as will be shown next, the hrHMW-FG apparently
completely lacks the phosphorylation on the FpA which is normally present in ~20% of the
chains [37]. Note also that the Aα chain C-terminally degraded species are likely to be
overestimated due to non-linearity effects in the Western blots staining, and for the
confounding effect of baseline noise on the smaller peaks. With these considerations in
mind, and assuming totally undegraded Bβ and γ chains, we report the global molecular
parameters computed for our three FG species in Table 2.
To further characterize our samples, we have studied the thrombin-induced fibrinopeptides
release. The results are shown in Fig. 3, with the peaks identified in panel C. Very similar
elution patterns were observed for hrα251-FG (panel A), hrHMW-FG (panel B), and
hpHMW-FG (panel C), with the two main forms present in the expected amounts. However,
some relevant differences were found in both the degraded and post-translational modified
forms of FpA, such as the absence of the FpAY form lacking the N-terminal alanine residue
in both the recombinant proteins, and of the phosphorylated FpAP form in the hrHMW-FG
sample alone. Instead, the degraded (desArgB lacking the C-terminal arginine residue,
FpBY2 lacking the N-terminal pyroglutamic acid and glycine residues) and deamidated
(N→D) forms of FpB [32] appears to be present in similar amounts in all species. While the
absence of FpAP in hrHMW-FG could be due to the particular expression system used [27],
the lack of FpAY in both recombinant species is likely due to in vivo processes of potential
physiological significance [37].
The results of the sedimentation velocity analyses are globally reported in Fig. 4 as
concentration-dependence plots of 1/s(20,w) (panel A) and (1 + ksc) × Dt(20,w) (panel B),
respectively, and the derived values are reported in Table 3. As can be seen in Fig. 4, most
of the samples yielded very good results, as indicated by the relatively small error bars; only
the Dt(20,w) data for hrα251-FG had greater uncertainties. The 1/s(20,w) vs. c plots of
hrHMW-FG and hpHMW-FG are practically superimposable, while a slight difference is
noticeable in the (1 + ksc) × Dt(20,w) vs. c plots for the same two species. The extrapolated
 and  are thus very similar for hrHMW-FG and hpHMW-FG (Table 3),
and in excellent agreement with literature values for unfractionated FG [5, 38–41]. As a
result, the weight-average molecular weights <M>w computed from the  and
 values via the Svedberg equation using the calculated  of Table 2, are also in
excellent agreement (within 1%) with those computed from the putative composition of the
hrHMW-FG and hpHMW-FG samples. As for hrα251-FG, the  and 
values are ~4% higher and ~12% lower, respectively, than those we previously found for
hpFrX-FG [26]. Comparing the new data with literature values for fragment X, the
 value matches well [42], while the  value is lower [43]. The slopes of
the 1/s(20,w) vs. c plots are also very similar for all the three species, leading to apparent
sedimentation concentration dependence “Grálen” coefficients ks of the same magnitude.
The positive ks value for hrα251-FG is in contrast with the slight negative value we
previously found for hpFrX-FG [26], and could reflect different thermodynamic behaviors
of the two species. Furthermore, practically identical negative values for the second virial
coefficient term BM1 were derived from the (1 + ksc) × Dt(20,w) vs. c plots for hrHMW-FG
and hpHMW-FG, indicating preferential interaction between the macromolecules, while
only a very slight concentration dependence was apparent for hrα251-FG, again in contrast
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with what we reported for hpFrX-FG [26]. In any case, we preferred to average all the
individual Dt(20,w) values to estimate  for this species. The resulting <M>w for
hrα251-FG is ~5% higher than the one calculated from its putative composition, which is
still satisfactory, given the uncertainty in the  value.
In conclusion, we have accurately determined the sedimentation and diffusion coefficients
of a well-characterized full length, intact recombinant human fibrinogen, and of its
counterpart purified from human plasma. No significant differences were found between the
recombinant and the plasma derived HMW-FGs, indicating a substantial overall structural
identity between the two samples. In addition, the recombinant full-length fibrinogen had a
better sample homogeneity. All these findings further confirm the suitability of recombinant
full-length fibrinogen species for structural studies, and they are of relevance for their
potential biotechnological/biomedical applications. We also determined the hydrodynamic
parameters for a recombinant fibrinogen with a truncated Aα chain (hrα251-FG) and
compared them with those of hpFrX-FG [26]. Although less accurately determined, the
observed differences in the  and ks values could stem from differences at the
molecular level, like the lack of both Bβ 1–52 segments in hpFrX-FG. This suggests a role
for these regions in FG-FG inter-molecular interactions. In any case, given the difficulties in
obtaining complete atomic-level structures of fibrinogen, these new hydrodynamic data will
constitute a reliable benchmark against which multi-resolution models could be compared.
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SDS-PAGE and Western blot analyses of the hrα251-FG, hrHMW-FG, and hpHMW-FG
samples. Panel A, non-reduced samples (3.75 μg/lane) run on a 3.2% PAA/8.5 M urea gel,
stained with Coomassie blue (due to the non-reducing conditions of the samples, the
molecular weight markers are just indicative). Panel B, reduced samples (7.5 μg/lane) run
on a 7.5% PAA gel, stained with Coomassie blue. Panel C, Western blot of the samples in
panel B (0.5 μg/lane) stained with the Y-18 mAb (pre-stained molecular weight markers on
the rightmost lane); the additional lane on the right side was loaded with 0.25 μg of
hrHMW-FG.
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Densitometry traces of the mAb Y18-stained Western blots of hrHMW-FG (panel A;
rightmost lane of Fig. 1, panel C) and hpHMW-FG (panel B; leftmost lane of Fig. 1, panel
C). In both panels the y-axis data were vertically shifted by subtracting a baseline value (no
rescaling was applied). The x-axis values of the panel B data where horizontally shifted to
find the best alignment between the main peaks in both panels. The corresponding
deconvolution results are shown in panels C and D, respectively. The color coding relates
the resulting EMG-GMG peaks to the data in Table 1: black, original curve; red,
reconstructed curve; blue, peak 1; green, peak 2; magenta, peak 3; grey, peak 4; cyan, peak
5; orange, peak 6; wine, peak 7; violet, peak 8; pink, peak 9.
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RP-HPLC analysis of fibrinopeptide content of hrα251-FG (panel A), hrHMW-FG (panel
B), and hpHMW-FG (panel C). The various Fps peaks are identified in panel C (FpAP,
phosphorylated FpA; FpAY, FpA lacking the N-terminal Ala residue; desArgB, FpB lacking
the C-terminal Arg residue; FpBY2, FpB lacking the N-terminal pyroGlu and Gly residues;
N→D, deamidated forms of all FpBs; the first “peak” in panel A is a spurious signal not
corresponding to any Fp species).
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Concentration-dependence plots of the reciprocal of the sedimentation coefficients (panel A)
and of the diffusion coefficients (panel B) derived from the SedFit analysis of sedimentation
velocity runs for hrα251-FG (open squares), hpHMW-FG (open circles), and hrHMW-FG
(open triangles). The straight lines are their respective weighted linear regressions (dashed,
hpHMW-FG).
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Table 1
Identification of the Aα-chain species in hrHMW-FG and hpHMW-FG, their calculated molecular parameters,
and relative % abundances derived from the densitometric analysis of Western blots.
Peak # Tentative identification Mass from composition E280 (ml mg−1 cm−1) Relative % (from gels)
a
hrHMW-FG
1 Aα1-610 (O-Gly) 66,751 1.03 0.710 3.5
2 Aα1-610 66,094 1.04 0.711 68.7
3 Aα1-601 65,105 1.06 0.711 21.1
4 Aα1-583 63,250 1.09 0.712 0.8
5 Aα1-554 60,022 1.07 0.713 0.7
6 Aα1-528 57,281 1.12 0.713 1.7
7 Aα1-508 55,033 1.17 0.713 1.2
8 Aα-461 50,111 1.28 0.713 1.9
9 Aα1-424 46,223 1.39 0.712 0.5
hpHMW-FG
1 Aα1-610 (O-Gly) 66,782 1.03 0.710 0.7
2 Aα1-610 66,125 1.04 0.711 28.8
3 Aα1-601 65,137 1.06 0.711 29.3
4 Aα1-583 63,282 1.09 0.712 23.8
5 Aα1-554 60,054 1.07 0.713 1.2
6 Aα1-528 57,313 1.12 0.713 0.5
7 Aα1-508 55,065 1.17 0.713 3.5
8 Aα1-461 50,143 1.28 0.713 11.2
9 Aα1-424 46,255 1.39 0.712 1.0
a
The amounts for peaks below ~2% should be considered just as an estimate.













Raynal et al. Page 16
Table 2
Calculated molecular properties of the hrα251-FG, hrHMW-FG, and hpHMW-FG species.
Species Molecular weight (g mol−1) E280 (ml mg−1 cm−1)
hrα251-FG 264,410a 0.720a 1.60a
hrHMW-FG 336,694 0.715 1.53
hpHMW-FG 331,683 0.715 1.55
a
Values derived from the theoretical composition only.













Raynal et al. Page 17
Table 3
Parameters derived from the analysis of the sedimentation velocity data.




hrα251-FG 7.09 ± 0.02 15.6 ± 4.9 0.6685 2.21 ± 0.05b ~0 NA 277,976 ± 6,287 (+5.1%)
hrHMW-FG 7.89 ± 0.02 13.3 ± 3.7 0.7228 1.98 ± 0.02 −92.7 ± −8.1 0.9705 339,164 ± 3,737 (+0.7%)
hpHMW-FG 7.84 ± 0.02 7.9 ± 5.1 0.3206 2.00 ± 0.01 −84.1 ± −10.0 0.9342 333,346 ± 1,032 (+0.5%)
a
% difference from the sequence-based MW adjusted according to SDS-PAGE/Western blot-derived values (only for hrHMW-FG and hpHMW-
FG, see Tables 1 and 2);
b
from the mean of the Dt(20,w) values.
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